Plant Name: Citrus maxima
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR1; GPBAR1; ADORA2B; FFAR4; | |
| TSHR; | |
| PTPRF; PTPN1; PTPN2; ACP1; | |
| TDP1; FAAH; RECQL; CTDSP1; TERT; PKM; HSD11B1; HSD17B1; AKR1B1; HSD17B10; ALOX15; AKR1B10; HSD17B2; ALDH1A1; GFER; NOX4; USP2; UBE2N; TNKS; TNKS2; POLB; | |
| ACHE; GAA; | |
| TRPV1; TRPA1; | |
| CFTR; | |
| CSNK2A1; DAPK1; SYK; FLT3; GSK3B; MAPK1; CDK6; | |
| CA7; CA3; CA14; CA5B; CA1; CA12; CA9; CA4; CA6; CA2; CA5A; | |
| PPARA; PPARG; PPARD; | |
| AR; | |
| THRB; | |
| NR1H4; | |
| NR1I2; | |
| ESRRA; | |
| RORC; | |
| ESR1; ESR2; | |
| MAOA; ALOX5; PTGS1; PTGS2; TYR; XDH; | |
| CASP7; CASP1; | |
| MMP2; MMP9; MMP1; | |
| TLR2; | |
| AHR; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; RAB9A; NPC1; XPO1; TTR; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2B6 | Cytochrome P450 2B6 | P20813 | CHEMBL4729 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
| Enzyme_unclassified | UBE2N | Ubiquitin-conjugating enzyme E2 N | P61088 | CHEMBL6089 |
| Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
| Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADORA2B | Adenosine A2b receptor | P29275 | CHEMBL255 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | XPO1 | Exportin-1 | O14980 | CHEMBL5661 |
| Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.461E-12 | 1.638E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4, PTGS1, PTGS2 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 8.212E-12 | 3.576E-09 | AHR, AR, ESR1, ESR2, ESRRA, NR1H4, NR1I2, PPARA, PPARD, PPARG, RORC, THRB, UBE2N |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.682E-11 | 6.912E-09 | CYP1A2, CYP2B6, CYP2C19, CYP2C9, CYP3A4, NR1I2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.222E-11 | 8.797E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.890E-11 | 1.746E-08 | ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 8.859E-11 | 2.837E-08 | AR, ESR1, ESR2, ESRRA, NR1H4, NR1I2, PPARA, PPARD, PPARG, RORC, THRB |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 4.818E-10 | 1.328E-07 | AR, CASP7, CFTR, CYP1A1, CYP1B1, ESR1, FLT3, MAPK1, NFKB1, NOX4, NPC1, PPARG, PTGS2, RORC, TRPV1 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 7.321E-10 | 1.898E-07 | AR, CYP3A4, ESR1, ESR2, ESRRA, HSD17B1, NPC1, NR1H4, RORC |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 8.299E-10 | 2.126E-07 | AR, ESR1, ESR2, ESRRA, NR1H4, NR1I2, PPARA, PPARD, PPARG, RORC, THRB |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.177E-10 | 2.324E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 9.508E-10 | 2.380E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.754E-09 | 4.196E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.088E-08 | 5.604E-06 | CA2, CA7, CFTR, HIF1A, MAPK1, NPC1, NR1H4, PTGS2, SYK, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.700E-07 | 2.588E-05 | CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.013E-07 | 3.006E-05 | CA2, CA7, CDK6, CFTR, HIF1A, MAPK1, NPC1, NR1H4, PTGS2, SYK, TNKS, TNKS2, TRPA1, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.512E-07 | 5.098E-05 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071396; cellular response to lipid | 3.895E-07 | 5.508E-05 | AR, CASP1, CDK6, CFTR, ESR1, FLT3, NFKB1, NPC1, NR1H4, PPARD, PPARG, RORC |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 5.667E-07 | 7.851E-05 | ABCC1, ALOX15, ALOX5, SYK, TLR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.697E-07 | 7.851E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0046456; icosanoid biosynthetic process | 1.418E-06 | 1.784E-04 | ALOX15, ALOX5, PTGS1, PTGS2, SYK |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.095E-06 | 3.643E-04 | ABCG2, ACHE, CASP1, CSNK2A1, DAPK1, ESR1, ESR2, FLT3, MAPK1, MAPT, MMP9, NFKB1, PKM, PPARG, PTGS2, RAB9A, TERT, TP53, TRPA1, TRPV1, TTR, TYR, USP2, XDH |
| MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 3.327E-06 | 3.874E-04 | AHR, ESR1, PPARA, TERT |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 4.093E-06 | 4.526E-04 | CYP1A1, POLB, PPARG, TP53 |
| BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 4.095E-06 | 4.526E-04 | FABP3, FFAR1, NR1H4, PPARG, PTGS2, TLR2 |
| MF | GO:0005488; binding | GO:0070324; thyroid hormone binding | 4.927E-06 | 5.131E-04 | PKM, THRB, TTR |
| CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 6.171E-06 | 6.308E-04 | CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, FAAH, HSD11B1, HSD17B2, NOX4, PTGS1, PTGS2, RAB9A |
| BP | GO:0009987; cellular process | GO:0080135; regulation of cellular response to stress | 8.035E-06 | 7.811E-04 | CDK6, GSK3B, HIF1A, MAPK1, MAPT, PTGS2, PTPN1, PTPN2, PTPRF, SYK, TERT, TP53, UBE2N, XDH |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 8.131E-06 | 7.834E-04 | MAPT, NOX4, PTGS2, TP53, TRPV1, XDH |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 8.513E-06 | 7.990E-04 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0050896; response to stimulus | GO:0009636; response to toxic substance | 9.038E-06 | 8.410E-04 | AHR, AKR1B1, CA3, CYP1A1, CYP1B1, MAPK1, NFKB1, POLB, TLR2, TP53, TRPA1 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 1.171E-05 | 1.024E-03 | ADORA2B, CYP1B1, HIF1A, PTGS2 |
| BP | GO:0008152; metabolic process | GO:0032270; positive regulation of cellular protein metabolic process | 1.340E-05 | 1.149E-03 | ADORA2B, ALOX15, AR, CASP1, CASP7, DAPK1, ESR1, FFAR4, FLT3, GSK3B, MAPK1, MAPT, MMP9, NOX4, PPARG, PTGS2, PTPN1, SYK, THPO, TP53, UBE2N, XDH |
| BP | GO:0009987; cellular process | GO:2001234; negative regulation of apoptotic signaling pathway | 1.616E-05 | 1.313E-03 | AR, DAPK1, HIF1A, LMNA, MMP9, PTGS2, PTPN1, TERT |
| MF | Unclassified; | GO:0004872; receptor activity | 1.641E-05 | 1.323E-03 | ADORA2B, AHR, AR, ESR1, ESR2, ESRRA, FFAR1, FFAR4, FLT3, GPBAR1, NPC1, NR1H4, NR1I2, PPARA, PPARD, PPARG, PTPRF, RORC, THRB, TLR2, TRPV1, TSHR |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 1.670E-05 | 1.332E-03 | CA2, CA7, CFTR |
| BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 1.670E-05 | 1.332E-03 | ABCC1, ABCG2, NR1I2 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 1.843E-05 | 1.454E-03 | ALOX15, CASP1, DAPK1, FABP4, FLT3, GSK3B, HIF1A, MAPK1, NFKB1, TRPV1 |
| BP | GO:0009987; cellular process | GO:0035690; cellular response to drug | 1.856E-05 | 1.459E-03 | AKR1B1, CDK6, CFTR, CYP1B1, MAPK1, NFKB1, PTGS2, TP53, TRPV1 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.867E-05 | 1.462E-03 | HIF1A, LMNA, PPARD, PTGS2, TERT, TP53 |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 1.963E-05 | 1.517E-03 | AR, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
| BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 2.287E-05 | 1.718E-03 | AR, CYP19A1, ESR1 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.352E-05 | 1.754E-03 | AHR, CSNK2A1, HIF1A, MAPT |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.522E-05 | 1.874E-03 | AHR, AKR1B1, ALOX5, AR, CASP7, CDK6, CSNK2A1, CTDSP1, ESR1, ESR2, ESRRA, FABP5, GSK3B, HIF1A, LMNA, MAPK1, NFKB1, NR1H4, NR1I2, POLB, PPARA, PPARD, PPARG, PTPN2, RECQL, RORC, TERT, THRB, TNKS, TP53, UBE2N, USP2, XPO1 |
| MF | GO:0005488; binding | GO:0019902; phosphatase binding | 2.627E-05 | 1.946E-03 | MAPK1, MAPT, PPARA, PPARG, PTPN1, SYK, TP53 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 2.770E-05 | 2.017E-03 | GAA, HIF1A, MAPK1, MAPT, NPC1, PPARA, PTGS2, THRB, TLR2, TP53, TRPV1, USP2 |
| MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 2.761E-05 | 2.017E-03 | PTGS1, PTGS2 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.761E-05 | 2.017E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 3.469E-05 | 2.461E-03 | AHR, AR, ESR1, GSK3B, PPARA, TP53 |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 3.935E-05 | 2.737E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0002376; immune system process | GO:0002682; regulation of immune system process | 4.235E-05 | 2.891E-03 | ADORA2B, AHR, ALOX15, CA2, CDK6, CYP19A1, ESR1, ESRRA, HIF1A, MAPK1, MMP2, NFKB1, NR1H4, PPARG, PTPN1, PTPN2, SYK, THPO, TLR2, TP53, UBE2N |
| BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 4.489E-05 | 3.045E-03 | HSD17B10, PKM, TP53, TRPA1, TRPV1 |
| BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 4.712E-05 | 3.177E-03 | MMP2, MMP9, PPARD, PTGS2 |
| BP | GO:0065007; biological regulation | GO:0043085; positive regulation of catalytic activity | 4.798E-05 | 3.225E-03 | ADORA2B, ALDH1A1, CASP1, CASP7, DAPK1, ESR1, FLT3, GSK3B, HIF1A, MAPK1, MAPT, NOX4, PPARG, PTPN1, SYK, TERT, TNKS, TSHR, UBE2N, XDH |
| BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 6.212E-05 | 4.099E-03 | TERT, TNKS, TNKS2 |
| BP | GO:0008152; metabolic process | GO:0006091; generation of precursor metabolites and energy | 7.256E-05 | 4.675E-03 | AKR1B1, CYP19A1, CYP1A2, GAA, GSK3B, NOX4, PKM, PPARD, XDH |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 7.354E-05 | 4.723E-03 | CASP1, CASP7, MAPT, PPARG, XDH |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 7.536E-05 | 4.826E-03 | ACP1, AHR, AKR1B1, AKR1B10, ALDH1A1, ALOX15, ALOX5, AR, CA1, CA2, CA3, CA7, CASP1, CASP7, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GFER, GSK3B, HIF1A, HSD17B1, LMNA, MAPK1, MAPT, NFKB1, PKM, PPARG, PTPN1, PTPN2, RAB9A, SYK, TNKS, TNKS2, TP53, TRPV1, TYR, UBE2N, XDH, XPO1 |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 7.616E-05 | 4.849E-03 | ALOX15, ALOX5, PTGS2 |
| BP | GO:0032501; multicellular organismal process | GO:0050968; detection of chemical stimulus involved in sensory perception of pain | 8.255E-05 | 5.049E-03 | TRPA1, TRPV1 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 8.255E-05 | 5.049E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.255E-05 | 5.049E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 8.255E-05 | 5.049E-03 | GPBAR1, NR1H4 |
| BP | GO:0032501; multicellular organismal process | GO:0050955; thermoception | 8.255E-05 | 5.049E-03 | TRPA1, TRPV1 |
| MF | GO:0005215; transporter activity | GO:0097603; temperature-gated ion channel activity | 8.255E-05 | 5.049E-03 | TRPA1, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 8.255E-05 | 5.049E-03 | ALOX15, PTGS2 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 8.255E-05 | 5.049E-03 | CYP1A1, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 8.255E-05 | 5.049E-03 | GPBAR1, NR1H4 |
| BP | GO:0002376; immune system process | GO:0045088; regulation of innate immune response | 8.398E-05 | 5.122E-03 | ESR1, MMP2, NFKB1, NR1H4, PPARG, PTPN1, PTPN2, SYK, TLR2, UBE2N |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 8.458E-05 | 5.130E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| BP | GO:0002376; immune system process | GO:0001774; microglial cell activation | 9.212E-05 | 5.427E-03 | MAPT, TLR2, TRPV1 |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 9.212E-05 | 5.427E-03 | MAPK1, TNKS, TNKS2 |
| BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 9.212E-05 | 5.427E-03 | CYP1A1, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 9.246E-05 | 5.427E-03 | MAPT, PTGS2, TP53, TRPV1 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 9.212E-05 | 5.427E-03 | CYP2B6, CYP2C19, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:1901653; cellular response to peptide | 1.180E-04 | 6.799E-03 | AKR1B1, GSK3B, NFKB1, PKM, PPARG, TP53, TSHR |
| BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 1.645E-04 | 8.868E-03 | TNKS, TNKS2 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.645E-04 | 8.868E-03 | PTPN1, PTPN2 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.645E-04 | 8.868E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.645E-04 | 8.868E-03 | ESR1, ESR2 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.645E-04 | 8.868E-03 | ALDH1A1, AR |
| BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 1.712E-04 | 9.201E-03 | PPARA, PPARG, RORC, TP53, USP2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.850E-23 | 4.972E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.422E-18 | 1.070E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.433E-15 | 3.116E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.259E-15 | 8.175E-12 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, MMP1, MMP2, MMP9, NR1H4, NR1I2, PPARA, PPARD, PPARG, PTPN1, RORC, THRB, TNKS, TP53 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.936E-14 | 2.205E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2B6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NOX4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 4.202E-22 | 7.690E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.632E-09 | 9.954E-08 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PTGS2; HIF1A; MMP9; NFKB1; AR; CDK6; MAPK1; PPARG; TP53; PPARD |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 5.377E-10 | 4.920E-08 | HSD11B1; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 6.079E-09 | 1.589E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 5.800E-09 | 1.589E-07 | CYP2C9; CYP2D6; MAOA; ALOX5; ALOX15; MAPK1; CYP2C19; PTGS2; PTGS1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.542E-09 | 1.296E-07 | HSD11B1; CYP2C9; CYP2B6; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.240E-09 | 1.025E-07 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.967E-08 | 9.089E-07 | MAOA; GAA; ALOX15; AKR1B1; PTGS2; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; PTGS1; HSD11B1; CYP2C9; CYP2B6; PKM; AKR1B10; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.847E-08 | 5.789E-07 | CYP2C9; CYP2B6; ALOX5; ALOX15; CYP2C19; PTGS2; PTGS1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 9.043E-09 | 2.069E-07 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.067E-08 | 9.252E-07 | CYP2C9; CYP2B6; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.901E-08 | 9.252E-07 | MMP1; DAPK1; MMP2; MAPK1; MMP9; TP53 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 9.821E-07 | 1.284E-05 | CYP2C9; CYP2B6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 6.212E-06 | 7.578E-05 | GSK3B; CDK6; CSNK2A1; RAB9A; TP53; NFKB1; TLR2 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.349E-05 | 2.687E-04 | PKM; FLT3; MAPK1; TP53; HIF1A |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 3.151E-05 | 3.204E-04 | GSK3B; THRB; MAPK1; TP53; ESR1; HIF1A |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.368E-07 | 4.740E-06 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.335E-05 | 3.212E-04 | GSK3B; MAPK1; ESR1; NFKB1; ESR2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 8.184E-05 | 6.807E-04 | MMP2; MAPK1; TP53; HIF1A; ESR1; MMP9; TLR2 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 8.702E-05 | 6.923E-04 | POLB; CDK6; PKM; SYK; MAPK1; TP53; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 3.116E-05 | 3.204E-04 | CA2; NR1H4; CYP3A4; CFTR; ABCG2 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.809E-05 | 3.485E-04 | PTPN1; CSNK2A1; MAPK1; ACP1; PTPRF |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.034E-04 | 7.566E-04 | CDK6; MAPK1; TP53; MMP9; NFKB1; TLR2 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 9.240E-05 | 7.045E-04 | GSK3B; AR; MAPK1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.411E-04 | 9.928E-04 | ABCC1; CDK6; CYP1B1; MAPK1; PTGS2; TP53; MMP9; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.529E-04 | 1.037E-03 | MMP2; MAPK1; ESR1; MMP9; ESR2 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 2.504E-04 | 1.414E-03 | CASP7; MAPK1; PTGS2; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.400E-04 | 1.414E-03 | PTPN1; GSK3B; PPARA; NFKB1; PTPRF |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 5.060E-05 | 4.410E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.910E-04 | 1.206E-03 | FABP4; PTGS2; TSHR; PTGS1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.047E-04 | 1.248E-03 | FLT3; MAPK1; NFKB1; PPARD |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 5.936E-04 | 2.612E-03 | GSK3B; XPO1; SYK; CSNK2A1; TP53; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.781E-04 | 1.164E-03 | CASP7; CASP1; NFKB1; TLR2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.563E-04 | 3.219E-03 | CASP7; LMNA; MAPK1; TP53; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.605E-04 | 1.941E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 5.298E-04 | 2.486E-03 | GSK3B; SYK; MAPK1; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.996E-04 | 2.612E-03 | GSK3B; MAPK1; PPARA; TP53; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.822E-03 | 6.947E-03 | GSK3B; CDK6; SYK; MAPK1; TP53; NFKB1; TLR2 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 5.298E-04 | 2.486E-03 | CDK6; MAPK1; TP53; NFKB1 |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 5.298E-04 | 2.486E-03 | MAPK1; PTGS2; NFKB1; TLR2 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.036E-03 | 7.604E-03 | GSK3B; XPO1; CASP1; MAPK1; NFKB1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.085E-03 | 7.632E-03 | POLB; GSK3B; XPO1; TERT; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.703E-03 | 6.631E-03 | GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 9.828E-04 | 4.087E-03 | CDK6; PTGS2; TP53; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 5.871E-04 | 2.612E-03 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 2.301E-03 | 8.258E-03 | FLT3; PPARG; TP53; MMP9; NFKB1 |
| hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 1.315E-03 | 5.348E-03 | SYK; CSNK2A1; PTGS2; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 3.543E-03 | 1.118E-02 | MAPK1; PPARA; CFTR; NFKB1; TSHR |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.137E-03 | 1.044E-02 | ALOX5; MAPK1; NFKB1; TLR2 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 3.332E-03 | 1.070E-02 | GSK3B; MAPK1; TP53; NFKB1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 3.332E-03 | 1.070E-02 | ABCC1; MAPK1; TP53; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 4.679E-03 | 1.381E-02 | SYK; MAPK1; PPARG; NFKB1 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 6.049E-03 | 1.685E-02 | GSK3B; CSNK2A1; TP53; PPARD |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 5.613E-03 | 1.630E-02 | PTPN1; GSK3B; MAPK1; PTPRF |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 7.490E-03 | 2.046E-02 | GSK3B; CASP7; PPARA; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.312E-02 | 3.381E-02 | SYK; MAPK1; NFKB1; TLR2 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.492E-02 | 3.556E-02 | CSNK2A1; TP53; NFKB1; TLR2 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.235E-02 | 3.228E-02 | PPARG; TP53; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.496E-02 | 3.556E-02 | MMP2; MAPK1; NFKB1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.457E-02 | 3.556E-02 | GSK3B; MAPK1; TYR |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.935E-03 | 1.013E-02 | CDK6; MAPK1; TP53 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.474E-03 | 1.342E-02 | CDK6; MAPK1; TP53 |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 1.496E-02 | 3.556E-02 | FAAH; MAPK1; PTGS2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.576E-02 | 3.699E-02 | MAPK1; HIF1A; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 5.726E-03 | 1.637E-02 | CDK6; MAPK1; TP53 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.374E-03 | 8.356E-03 | GSK3B; MAPK1; TP53 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.701E-02 | 3.843E-02 | MAPK1; NFKB1; TLR2 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.617E-02 | 3.700E-02 | GSK3B; MAPK1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 9.706E-03 | 2.612E-02 | CASP1; MAPK1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.617E-02 | 3.700E-02 | MAPK1; NFKB1; TLR2 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.916E-03 | 1.215E-02 | GSK3B; MAPK1; TP53 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.086E-03 | 1.044E-02 | CASP1; MAPK1; NFKB1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 4.273E-04 | 2.234E-03 | MAPK1; PPARG; TP53 |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 4.474E-03 | 1.342E-02 | RORC; NFKB1; TLR2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 4.731E-04 | 2.405E-03 | AKR1B10; GAA; AKR1B1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.465E-03 | 5.830E-03 | ABCC1; CFTR; ABCG2 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.374E-02 | 3.491E-02 | MAOA; TYR |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.156E-02 | 3.067E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.450E-02 | 3.556E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.077E-03 | 1.685E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.550E-04 | 1.414E-03 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; SYK; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5; TRPV1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1; PPARG; PPARD; PPARD |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1; ESRRA; FFAR1; ADORA2B |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| NA: NA | HIV infections | NA | AHR |
| A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| A00-B99: Certain infectious and parasitic diseases | Herpes simplex virus infection | B00 | ADORA2B |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; TP53 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1; ESR1 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| NA: NA | Dyslipidemia | NA | PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; ESRRA; ALOX5; SYK; CASP1; PTGS2; PTGS2; PTGS2; PTGS2; TYR; MMP1 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| NA: NA | Male hypogonadism | NA | AR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; PPARG |
| NA: NA | Edema | NA | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
| NA: NA | Menopausal disorder | NA | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; TYR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TLR2; PKM; SYK; FLT3; CA9; MMP2; HIF1A; MAPK1; MMP9; TP53; XPO1 |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | TRPV1 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; TRPV1; PTGS1; PTGS2; PTGS2 |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; TERT; FLT3; FLT3; CA9; CYP19A1; ESR1; ESR1 |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | TRPV1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | HSD11B1; HSD11B1; AKR1B1; PTPN1; FFAR1; GSK3B; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | GSK3B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
| NA: NA | Miosis during ocular surgery | NA | PTGS1 |
| I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; MMP9; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; TRPV1; PTGS1 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | TRPV1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; TERT |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; TLR2; CSNK2A1; SYK; CA1; FLT3; FLT3; CA9; MMP2; ACHE; PTGS2; GSK3B; HIF1A; MAPK1; MMP9; NFKB1; TP53; ESR1; ESR1; XPO1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
| A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5; SYK |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; ACHE; FAAH; CYP3A4 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| NA: NA | Joint and muscular pain | NA | PTGS2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pathological pain | R52, G89 | TRPV1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Acute or chronic pain | R52, G89 | TRPV1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | TRPV1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; FLT3; FLT3; TP53; TP53 |
| NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; PPARG; PPARG |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| I00-I99: Diseases of the circulatory system | Paroxysmal supraventricular tachycardia | I47-I49, I47.1, I47.2, R00.0 | ADORA2B |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; ACHE; TRPV1; TRPV1; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; TRPA1; FAAH; ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2; TERT; FLT3; MMP2; PTGS2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; ESR1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | TRPV1; TRPV1 |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | TRPV1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; FFAR1; PTGS2; NFKB1; PPARG; PPARG; GPBAR1; PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; THRB |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; TERT; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB; PPARD; ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | TTR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; HIF1A |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | FAAH |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; NR1I2; ALOX5; PPARD |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Apnea | R06.81 | ADORA2B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; ALOX5; ALOX5; SYK; SYK; TRPV1; PTGS2; ADORA2B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ABCC1; ESRRA; ALOX5; PTGS2; PTGS2; MMP1 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| NA: NA | Esophagus sensitivity | NA | TRPV1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; SYK; PTGS1; PTGS2; FAAH |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; CA2 |